About us
TargED is a spin-off of the University Medical Center Utrecht, founded in July 2020 by Coen Maas, Steven de Maat, Marc van Moorsel and Kristof Vercruysse. Coen, Steven and Marc hold a PhD in the field of thrombosis and hemostasis from Department of Clinical Chemistry and Haematology at UMC Utrecht. Kristof has more than 20 years of experience in bringing biopharmaceutical compounds from pre-clinical proof of concept to market, most notably, Caplacizumab for Thrombotic Thrombocytopenic Purpura at Ablynx between 2007 and 2013. Since 2020, TargED raised more than €45 million of funding and expanded the team to >15 people.
